Initial low-dose aminoglycosides in staphylococcus aureus bacteremia: Good science, urban legend, or just plain toxic?

Clinical Infectious Diseases

Volumn 48, Issue 6, 2009, Pages 722-724

  Bayer, Arnold S ^a,c   Murray, Barbara E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CREATININE; DAPTOMYCIN; METICILLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CREATININE CLEARANCE; DIABETES MELLITUS; ERADICATION THERAPY; HUMAN; IMMUNE COMPLEX NEPHRITIS; IN VIVO STUDY; INFECTION RISK; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCAL BACTEREMIA; TREATMENT DURATION; TREATMENT OUTCOME; BACTEREMIA; DRUG COMBINATION; DRUG EFFECT; EDITORIAL; ISOLATION AND PURIFICATION; KIDNEY; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 62449261086     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597032     Document Type: Review

References (12)

1. Sande MA, Courtney KB. Nafcillin-gentami-cin synergy in experimental staphylococcal endocarditis. J Lab Clin Med 1976;88:118-24.
2. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982;97:496-503.
3. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109:619-24.
4. Le T, Bayer AS. Combination antibiotic therapy lor infective endocarditis. Clin Infect Dis 2003;36:615-21.
5. Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endo-carditis and its complications. Circulation 1998;98:2936- 48.
6. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 1 l:e394-434.
7. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 2006; 355:653-65.
8. Cosgrove SE, Vigliani GA, Campion M, et al.Initial low-dose gentamicin tor S. aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48:713-21( in this issue)
9. Goetz MB, Sayers J. Nephrotoxicity of vanomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1990;25:679-87.
10. Neugarten J, Baldwin DS. Glomerulonephritis in bacterial endocarditis. Am J Med 1984; 77:297-304.
11. Carrier D, Bou Khalil M, Kealey A. Modulation of phospholipase A2 activity by aminoglycosides and daptomycin: a Fourier transform infrared spectroscopic study. Biochemistry 1998;37:7589-97.
12. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.